Provided by Tiger Trade Technology Pte. Ltd.

Kyverna Therapeutics

6.22
-0.3000-4.60%
Post-market: 6.250.0300+0.48%19:57 EDT
Volume:1.18M
Turnover:7.45M
Market Cap:384.67M
PE:-2.16
High:6.75
Open:6.62
Low:6.17
Close:6.52
52wk High:13.67
52wk Low:5.30
Shares:61.84M
Float Shares:39.72M
Volume Ratio:1.22
T/O Rate:2.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8809
EPS(LYR):-3.6445
ROE:-87.24%
ROA:-44.51%
PB:2.32
PE(LYR):-1.71

Loading ...

Kyverna Therapeutics Highlights Updated Miv-Cel Data at Eular Demonstrating Substantial Reduction in Disease Activity in Acpa-Positive, Treatment Refractory Rheumatoid Arthritis

THOMSON REUTERS
·
Jun 03

Kyverna Therapeutics - Miv-Cel Demonstrates Well-Tolerated Safety Profile in Over 100 Patients

THOMSON REUTERS
·
Jun 03

Kyverna Therapeutics - Majority of Patients Meet Acr70 Response by Week 36 in Miv-Cel Phase 1 Trial

THOMSON REUTERS
·
Jun 03

Kyverna Therapeutics Stockholders Approve Directors and Auditor

TIPRANKS
·
Jun 03

Kyverna Therapeutics shareholders elect two directors at annual meeting

Reuters
·
Jun 03

H.C. Wainwright Reaffirms Their Buy Rating on Kyverna Therapeutics, Inc. (KYTX)

TIPRANKS
·
May 27

Kyverna names CFO Gregory S. Martini in initial beneficial ownership filing

Reuters
·
May 21

Kyverna Therapeutics Names Gregory Martini as New CFO

TIPRANKS
·
May 18

Kyverna names Greg Martini CFO, succeeding Marc Grasso

Reuters
·
May 18

Kyverna Therapeutics Inc - Greg Martini Succeeds Marc Grasso as CFO

THOMSON REUTERS
·
May 18

Kyverna Therapeutics Names Greg Martini as Chief Financial Officer

THOMSON REUTERS
·
May 18

Kyverna Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 15

Kyverna Therapeutics price target raised to $25 from $20 at H.C. Wainwright

TIPRANKS
·
May 15

Kyverna Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire
·
May 14

Kyverna Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
May 13

Analysts Conflicted on These Healthcare Names: Kyverna Therapeutics, Inc. (KYTX), Immunome (IMNM) and Prime Medicine, Inc. (PRME)

TIPRANKS
·
May 13

Kyverna Therapeutics price target lowered to $29 from $30 at JPMorgan

TIPRANKS
·
May 13

Wells Fargo Remains a Buy on Kyverna Therapeutics, Inc. (KYTX)

TIPRANKS
·
May 13

Kyverna Therapeutics reports Q1 EPS (66c), consensus (73c)

TIPRANKS
·
May 13

BRIEF-Kyverna Therapeutics Reports First Quarter 2026 Financial Results

Reuters
·
May 13